Effects of a human compact anti-ErbB2 antibody on prostate cancer

Angela Eliana Malara, Carmine Fedele, Luigi Aloj, Claudio Arra, Paolo Laccetti, Giuseppe D'Alessio, Claudia De Lorenzo

Research output: Contribution to journalArticle

Abstract

Prostate cancer is the most commonly diagnosed malignancy in men in developed countries. ErbB2, a tyrosine kinase receptor overexpressed in many human cancer types, contributes to prostate cancer progression by activating the androgen receptor in a steroid poor environment, thus promoting androgen-independent cell growth. The consequent development of hormone refractory tumors is a major obstacle in prostate cancer therapy. The inhibition of ErbB2 signal transduction pathways by the use of human antibodies could be a valuable alternative strategy for cancer therapy. We performed a comparative analysis in vitro and in vivo of the antitumor effects of three different antibodies targeting different epitopes of ErbB2: Herceptin (trastuzumab), 2C4 (pertuzumab) and Erb-hcAb (human anti-ErbB2-compact antibody), a novel fully human compact antibody produced in our laboratory. Herein, we demonstrate that the growth of both androgen-dependent and independent prostate cancer cells was efficiently inhibited by Erb-hcAb. The antitumor effects induced by Erb-hcAb on some cell lines were more potent than those observed for either Herceptin or 2C4. Thus, Erb-hcAb could be a promising candidate in the immunotherapy of prostate cancer for which no obvious treatment has been reported so far.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalOncology Reports
Volume28
Issue number1
DOIs
Publication statusPublished - Jul 2012

    Fingerprint

Keywords

  • Antibodies
  • ErbB2/Her2
  • Herceptin/trastuzumab
  • Immunotherapy
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Malara, A. E., Fedele, C., Aloj, L., Arra, C., Laccetti, P., D'Alessio, G., & De Lorenzo, C. (2012). Effects of a human compact anti-ErbB2 antibody on prostate cancer. Oncology Reports, 28(1), 297-302. https://doi.org/10.3892/or.2012.1760